SL 701

Drug Profile

SL 701

Alternative Names: Brain cancer vaccine - Stemline Therapeutics; SL-701

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pittsburgh
  • Developer Stemline Therapeutics; University of Pittsburgh
  • Class Brain cancer vaccines; Dendritic cell vaccines; Immunotherapies; Peptides; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Glioma

Most Recent Events

  • 05 Jun 2018 Interim efficacy and adverse events data from a phase I/II trial in Glioblastoma released by Stemline Therapeutics
  • 05 Jun 2018 Stemline Therapeutics plans a registrational clinical trials for Glioblastoma (in combination with bevacizumab)
  • 22 Jan 2018 Stemline completes a phase I/II trial in Glioblastoma (Recurrent, Second-line therapy or greater, In adults, Combination therapy) in USA (SC) (NCT02078648)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top